Advances in an In Vitro Tuberculosis Infection Model Using Human Lung Organoids for Host-Directed Therapies

PLoS Pathog. 2024 Jul 25;20(7):e1012295. doi: 10.1371/journal.ppat.1012295. eCollection 2024 Jul.

Abstract

The emergence of drug-resistant Mycobacterium tuberculosis (M.tb) has led to the development of novel anti-tuberculosis (anti-TB) drugs. Common methods for testing the efficacy of new drugs, including two-dimensional cell culture models or animal models, have several limitations. Therefore, an appropriate model representative of the human organism is required. Here, we developed an M.tb infection model using human lung organoids (hLOs) and demonstrated that M.tb H37Rv can infect lung epithelial cells and human macrophages (hMφs) in hLOs. This novel M.tb infection model can be cultured long-term and split several times while maintaining a similar number of M.tb H37Rv inside the hLOs. Anti-TB drugs reduced the intracellular survival of M.tb in hLOs. Notably, M.tb growth in hLOs was effectively suppressed at each passage by rifampicin and bedaquiline. Furthermore, a reduction in inflammatory cytokine production and intracellular survival of M.tb were observed upon knockdown of MFN2 and HERPUD1 (host-directed therapeutic targets for TB) in our M.tb H37Rv-infected hLO model. Thus, the incorporation of hMφs and M.tb into hLOs provides a powerful strategy for generating an M.tb infection model. This model can effectively reflect host-pathogen interactions and be utilized to test the efficacy of anti-TB drugs and host-directed therapies.

MeSH terms

  • Antitubercular Agents* / pharmacology
  • Antitubercular Agents* / therapeutic use
  • Epithelial Cells / microbiology
  • Humans
  • Lung* / microbiology
  • Lung* / pathology
  • Macrophages / microbiology
  • Mycobacterium tuberculosis* / drug effects
  • Organoids* / microbiology
  • Tuberculosis / drug therapy
  • Tuberculosis / microbiology
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Antitubercular Agents

Grants and funding

This research was supported by the Korea National Institutes of Health (NIH) (No. 2021-ER2001-00) awarded to E.M.K., the Korea Institute of Toxicology, Republic of Korea (No. 1711195891) awarded to E.M.K., the Korea Environment Industry & Technology Institute (KEITI) through Technology Development Project for Safety Management of Household Chemical Products, funded by Korea Ministry of Environment (MOE) (RS-2022-KE002021) awarded to E.M.K., the Seoul Women’s University (2024-0049) awarded to E.M.K., and the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) (No. 2022R1C1C2011153) awarded to J.A.C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.